Full-Time

Director – Precision Medicine and Companion Diagnostics

Updated on 6/3/2024

Revolution Medicines

Revolution Medicines

201-500 employees

Specializes in precision oncology therapies

Biotechnology

Compensation Overview

$195k - $245kAnnually

+ Equity

Senior

San Carlos, CA, USA

Required Skills
Communications
Requirements
  • Ph.D. in cancer biology, cell/molecular biology, genomics or equivalent with 6+ years of industry experience
  • 3+ years of experience in CDx development
  • Broad knowledge and understanding of established and novel technologies employed in clinical diagnostic assays (e.g. NGS, IHC, PCR)
  • Excellent scientific and business communication skills
  • Strong interpersonal/collaboration skills and planning skills
  • Ability to think critically and creatively
  • Ability to work independently to determine appropriate resources for problem resolution
  • Ability to multi-task and thrive in a fast-paced innovative environment
  • Commitment to Revolution Medicines’ Core Values
Responsibilities
  • Drive implementation of the CDx strategy to support early and late-stage development of portfolio assets
  • Lead or participate in joint project teams (JPTs) with diagnostic partners and internal cross-functional team members
  • Collaborate with biomarker scientists, biomarker operations, clinical development, and clinical operations
  • Collaborate with diagnostic partners and internal functions to enable regulatory submissions
  • Manage contracts, budgets, and timelines associated with CDx development
  • Develop plans for publication of diagnostic test results
  • Develop patient identification strategies for launch readiness

### Welcome to Revolution Medicines, crafting the future of oncology with precision. Our focus is on advancing RAS(ON) inhibitors and RAS Companion inhibitors, marked by the remarkable journey of our lead product, RMC-4630, through its clinical phases. Supported by a team of passionate oncology experts, we are steadfast in our mission to develop treatments that precisely target oncogenic mutations, promising a brighter, healthier tomorrow for patients everywhere. ###

Company Stage

IPO

Total Funding

$1.3B

Headquarters

Redwood City, California

Founded

2014

Growth & Insights
Headcount

6 month growth

18%

1 year growth

48%

2 year growth

98%